{"name":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","slug":"mdd-us-operations-llc-a-subsidiary-of-supernus-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2004-01-01","label":"APOKYN first approved","drug":"APOKYN","drugSlug":"apokyn","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APOKYN","genericName":"APOKYN","slug":"apokyn","indication":"Parkinson's disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"apomorphine infusion","genericName":"apomorphine infusion","slug":"apomorphine-infusion","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"APOKYN","genericName":"APOKYN","slug":"apokyn","phase":"marketed","mechanism":"D(2) dopamine receptor","indications":["Parkinson's disease"],"catalyst":""},{"name":"apomorphine infusion","genericName":"apomorphine infusion","slug":"apomorphine-infusion","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNeWxzZXRrcVFKTXJ3M0ptUWNrbWhyRDhXS081TTNFUnpPQmc4YktkRS03R1NsR3EtYVJIWHlpMGdWYlo2Z21sQ2JBWUNFWTVUdkZ1RE9yXy0xSExuZTFvUFZXSTRCYUhYTUJaUUJJZGJIRFdWajVpV0Q5QVo1SDdxMDNzUV9Md0x5aUNvZGhhaU5rRWpVMl82RC0zcWJ1QmRUbnZ2UXNhY1FXeDFuYXVHbThoMWNETEYtMXhwVmhUeWdyLXJsSFgyM2d1RnpuTXFyaFZuRWVoZjlhVmNVb3JtLU85RHZxMGJQMlh4RFplR3NTOTFMeGI0X2NkNDNHNTRBSktmMnpTb1M4ZlZHZ2c?oc=5","date":"2025-06-16","type":"deal","source":"GlobeNewswire","summary":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire","headline":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}